Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report released on Monday,Benzinga reports. They currently have a $68.00 price target on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on HALO. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Finally, Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Stock Down 0.4 %

Shares of HALO opened at $47.81 on Monday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The business has a fifty day moving average of $50.14 and a 200 day moving average of $54.01. The company has a market cap of $6.08 billion, a PE ratio of 15.83, a P/E/G ratio of 0.44 and a beta of 1.23. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total transaction of $525,800.00. Following the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $35,583,199.52. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics in the 2nd quarter worth $33,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Halozyme Therapeutics in the second quarter worth about $49,000. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth about $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $65,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.